Literature DB >> 24074141

Typical and atypical antipsychotics do not differ markedly in their reversibility of antagonism of the dopamine D2 receptor.

Kristoffer Sahlholm1, Daniel Marcellino, Johanna Nilsson, Sven Ove Ögren, Kjell Fuxe, Peter Århem.   

Abstract

It has been suggested that the favorable side-effect profiles of atypical antipsychotics (e.g. clozapine and amisulpride) are related to their ∼100-fold faster dissociation from dopamine D2 receptors (D2R) compared with typical antipsychotics (e.g. haloperidol and chlorpromazine). Fast dissociation would entail rapidly reversible antagonism; however, this has not been thoroughly studied using functional assays. We compared the reversibilities of D2R antagonism by 17 compounds using an electrophysiological method to measure dopamine-evoked potassium channel activation via D2R. Varying rates and amplitudes of D2R response recovery were observed following antagonist removal. Whereas recovery rates differed 15-fold between atypical drugs, recovery from clozapine and amisulpride antagonism was, unexpectedly, less than twofold faster than from chlorpromazine. The recovery amplitude correlated with calculated water solubility and lipid/water distribution coefficients, suggesting variable drug partitioning into cell membranes. Our data do not support the notion that the rate of reversibility of D2R antagonism is what distinguishes atypical from typical antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24074141     DOI: 10.1017/S1461145713000801

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  6 in total

Review 1.  Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia.

Authors:  Dasiel O Borroto-Escuela; Julia Pintsuk; Thorsten Schäfer; Kristina Friedland; Luca Ferraro; Sergio Tanganelli; Fang Liu; Kjell Fuxe
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-10

2.  Antipsychotics with similar association kinetics at dopamine D2 receptors differ in extrapyramidal side-effects.

Authors:  Hugo Zeberg; Kristoffer Sahlholm
Journal:  Nat Commun       Date:  2018-09-03       Impact factor: 14.919

3.  Reply to 'Antipsychotics with similar association kinetics at dopamine D2 receptors differ in extrapyramidal side-effects'.

Authors:  David A Sykes; J Robert Lane; Monika Szabo; Ben Capuano; Jonathan A Javitch; Steven J Charlton
Journal:  Nat Commun       Date:  2018-09-03       Impact factor: 14.919

4.  Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses.

Authors:  Kristoffer Sahlholm; Jurgen W A Sijbesma; Bram Maas; Chantal Kwizera; Daniel Marcellino; Nisha K Ramakrishnan; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde
Journal:  Psychopharmacology (Berl)       Date:  2015-07-11       Impact factor: 4.530

5.  Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors.

Authors:  David A Sykes; Holly Moore; Lisa Stott; Nicholas Holliday; Jonathan A Javitch; J Robert Lane; Steven J Charlton
Journal:  Nat Commun       Date:  2017-10-02       Impact factor: 14.919

6.  Ligand with Two Modes of Interaction with the Dopamine D2 Receptor-An Induced-Fit Mechanism of Insurmountable Antagonism.

Authors:  Richard Ågren; Hugo Zeberg; Tomasz Maciej Stępniewski; R Benjamin Free; Sean W Reilly; Robert R Luedtke; Peter Århem; Francisco Ciruela; David R Sibley; Robert H Mach; Jana Selent; Johanna Nilsson; Kristoffer Sahlholm
Journal:  ACS Chem Neurosci       Date:  2020-09-15       Impact factor: 4.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.